Skip to content
Research Article Open access CC BY 4.0

A New Hope in Alzheimer's Treatment; Lecanemab

Zainab Zaki Abdulkarim Alkhamis, Sofia Ahmed Alkhatibi Alfalasi

International Neuropsychiatric Disease Journal · pp. 40–45 · Published 6 Mar 2023

10.9734/indj/2023/v19i1365

Abstract

Lecanemab's apparent effectiveness follows years of disillusionment with earlier, comparable medications that were meant to delay or stop the course of Alzheimer's disease. It contains monoclonal antibodies that were created in laboratories with the goal of purging the brain of a material called as beta-amyloid, exactly like a lot of those other medicines. People with Alzheimer's disease tend to have an accumulation of beta-amyloid in their brains, which leads to the development of the sticky plaques that have come to be associated with the condition. As a result of this, the objective of his research paper is to investigate background information about the drug lecanemab. In addition to this, the study offers information regarding the approval procedure for lecanemab, the drug's mode of action, and, lastly, the most recent discoveries.

Lecanemab monoclonal antibodies alzheimer's drug target

References (9)

  1. 1 Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study [DOI]
  2. 2 Lecanemab in Early Alzheimer’s Disease [DOI]
  3. 3 Long-Term Health Outcomes of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling [DOI]
  4. 4 The Potential Economic Value of Lecanemab in Patients with Early Alzheimer’s Disease Using Simulation Modeling [DOI]
  5. 5 Population pharmacokinetic‐pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease [DOI]
  6. 6 Lecanemab trial finds slight slowing of cognitive decline, but clinical benefits are uncertain [DOI]
  7. 7 Modeled Impact of APOE4 Genotype on ARIA‐E Incidence in Patients Treated With Lecanemab [DOI]
  8. 8 Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Lecanemab in Healthy Subjects [DOI]
  9. 9 Preliminary assessment of the clinical effects of lecanemab following 18 months of treatment in the open label extension of the phase 2 proof of concept study, BAN2401‐G000‐201, in subjects with early Alzheimer’s disease [DOI]

Cited by 4

Lecanemab: A Hopeful Alzheimer’s Disease Treatment

Zaib Un Nisa Mughal, Bisma Ahmed, Fatima Amin · Annals of Neurosciences · 2023

Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application

Nandhini Jayaprakash, Karthikeyan Elumalai · Chronic Diseases and Translational Medicine · 2024

Showing 2 of 4 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

31

Page views

0

PDF downloads

4

Outbound clicks

4

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.